First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?

Table 2 Ongoing studies of first-line treatments for HER2 positive metastatic breast cancer

Study	Arms of Treatment	Population	N. of patients	Obiectives of Study
Peruse (MO28047)	P + T + Tx	mBC HER 2+	1436	Multicenter clinical practice, single-arm phase IV study to evaluate the safety of the combination in real life world
Pertain (MO27775)	P + T + AI vs T + AI	mBC HER2+ HR+ Post menopausal status	250	Randomized multicenter open label phase II study designed to assess the efficacy and safety of P+ T + AI [anastrozole or letrozole) or T+ AI. Pts in either arm may also receive induction chemotherapy for up to 18 weeks at the investigator’s discretion.
Velvet (MO27782)	P + T + VNR	mBC HER2+	210	Randomized, multicenter open-label, single-arm with 2 cohorts of patients (cohort 1 = sequential infusion of P and T; cohort 2 concomitant P and T) designed to evaluate the efficacy and safety of P in combination with VNR
Metapher (BO29159)	P + T (s.c) + Tx	mBC HER2+	400	Multicenter single-arm phase IIIb study, designed to evaluate the safety and efficacy of the combination P + T subcutaneously + Tx

P Pertuzumab, T Trastuzumab, Tx Docetaxel or Paclitaxel or nabPaclitaxel, VNR Vinorelbine, AI aromatase inhibitor, mBC metastatic Breast Cancer, s.c. subcutaneous

ISSN: 1756-9966